Take action to slow GA
SYFOVRE is the longest-studied FDA-approved treatment for GA, studied in
2 clinical trials with
1,200 people and over
10,000 treatments given
SYFOVRE was proven to slow lesion growth in people treated with SYFOVRE versus those who were not.
Trial 1
After 2 years, compared to those who did not receive SYFOVRE, SYFOVRE slowed lesion growth by
monthly
(n=202)
every other month
(n=205)
Trial 2
After 2 years, compared to those who did not receive SYFOVRE, SYFOVRE slowed lesion growth by
monthly
(n=201)
every other month
(n=201)
GA cannot be cured, and the damage cannot be reversed. However, slowing lesion growth can delay disease progression.